trending Market Intelligence /marketintelligence/en/news-insights/trending/8Fqa7f071nbEykwtjsqHNw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioMarin submits gene therapy for US FDA review; filing accepted by EMA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioMarin submits gene therapy for US FDA review; filing accepted by EMA

BioMarin Pharmaceutical Inc. submitted a biologics license application for its gene therapy valoctocogene roxaparvovec to the U.S. Food and Drug Administration and received acceptance of the treatment's application from the European Medicines Agency.

The San Rafael, Calif.-based biotechnology company's therapy treats adult patients with hemophilia A, a disorder that causes potentially life-threatening bleeding complications resulting from a missing or defective factor VIII protein.

The company's submissions of valoctocogene roxaparvovec are based on an ongoing phase 1/2 trial in which the drug reduced bleeding in hemophilia patients by 96% over three years and internal data from an ongoing phase 3 trial.

BioMarin expects the review processes for the drug to start in January 2020 for the EMA and February 2020 for the FDA.

In October, the EMA granted valoctocogene roxaparvovec accelerated assessment, which reduces review time to 150 days from 210 days, although the agency's support for the drug dates back to 2017 when it gave the drug access to its priority medicines regulatory initiative.

Both the EMA and the FDA have given the therapy orphan designations and the U.S. regulator has also tagged it as a breakthrough therapy.